CPS Capital Investor Note: “Speculative Buy”
CPS Capital CEO, Jason Peterson advised current and potential investors that as a major shareholder of Cynata Therapeutics Ltd (“CYP”), he has recently been meeting management, organising a marketing strategy for the company & and generally understanding the stem cell market.
Mr Peterson provided the following information to investors:
This company is impressive and has the ability to deliver. The current “negatives” around the stock are being addressed (these are minor in the whole scheme of things).
Based on this and further to recent information released by the company CYP is currently a SPECULATIVE BUY.